加载中
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
前收盘价
US$88.15
−US$0.90 · -1.01%
盘中时间采用ET。市场数据可能有所延迟。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日内区间
当前US$88.15
52周区间
当前US$88.15
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
31
偏贵
情绪
55
多空交织
风险
35
中等风险
动量
65
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日内区间
当前US$88.15
52周区间
当前US$88.15
营业利润
净利润
| 项目（EUR） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | 5076.4万 EUR | 4551.7万 EUR |
| 毛利 | — | — | — | −5076.4万 EUR | −4551.7万 EUR |
| 研究与开发 | 1.78亿 EUR | 1.47亿 EUR | 1.03亿 EUR | 4829.5万 EUR | 4778.1万 EUR |
| 销售、一般及管理费用 | 7286.5万 EUR | 3890万 EUR | 2882.2万 EUR | 749.3万 EUR | 557.9万 EUR |
| 营业费用 | 2.46亿 EUR | 1.73亿 EUR | 1.27亿 EUR | 1407.2万 EUR | −411.7万 EUR |
| 利息收入 | 575.3万 EUR | 895.6万 EUR | 277.3万 EUR | — | — |
| 利息支出 | 2848.2万 EUR | 1243.1万 EUR | 1382.6万 EUR | 694万 EUR | 355.8万 EUR |
| 折旧和摊销 | 107.2万 EUR | 110万 EUR | 70.7万 EUR | 48.5万 EUR | 30.2万 EUR |
| 营业利润 | −2.46亿 EUR | −1.73亿 EUR | −1.27亿 EUR | −6483.6万 EUR | −4140万 EUR |
| 净利润 | −3.36亿 EUR | −1.76亿 EUR | −1.48亿 EUR | −6074万 EUR | −4245.2万 EUR |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$156
上涨空间 76.97%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB5015.22万0.48%108.2亿 USD0.44%US$206.49+3.00%
Schwab International Equity ETFSCHF1624.06万0.02%674.08亿 USD0.03%US$27.27+0.66%
Goldman Sachs Hedge Industry VIP ETFGVIP922.66万1.59%5.79亿 USD0.45%US$172.85+0.79%
State Street SPDR Portfolio Developed World ex-US ETFSPDW530.86万0.01%404.62亿 USD0.03%US$49.98+0.64%
Vanguard Total International Stock ETFVXUS316.37万0.00%6657亿 USD0.05%US$84.82+0.86%
Militia Long/Short Equity ETFORR289万0.83%3.46亿 USD10.91%US$38.52+1.02%
Vanguard FTSE Developed Markets ETFVEA210.48万0.00%3238亿 USD0.03%US$70.35+0.70%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM166.69万0.24%6.94亿 USD0.89%US$57.70+0.92%iShares Biotechnology ETFIBBSchwab International Equity ETFSCHFGoldman Sachs Hedge Industry VIP ETFGVIPState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Total International Stock ETFVXUSMilitia Long/Short Equity ETFORRVanguard FTSE Developed Markets ETFVEAMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
